Harris, Katie
Oshima, Megumi
Sattar, Naveed
Würtz, Peter
Jun, Min
Welsh, Paul
Hamet, Pavel
Harrap, Stephen
Poulter, Neil
Chalmers, John
Woodward, Mark
Funding for this research was provided by:
University of Oxford
Article History
Received: 5 December 2019
Accepted: 1 April 2020
First Online: 8 May 2020
Authors’ relationships and activities
: MW reports consultancy fees from Amgen and Kirin and is supported by an Australian NHMRC fellowship (APP1080206) and MRC program grant (APP1149987). JC received research grants from the NHMRC of Australia and from Servier for the ADVANCE trial and ADVANCE-ON post-trial follow-up, and honoraria for speaking about these studies at scientific meetings; he also reports grant support from a program grant (APP1149987) from the NHMRC of Australia. MJ reports receiving grant support from the NHMRC of Australia (project grant: 1148060) and unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. PWü is an employee and shareholder of Nightingale Health Ltd., which conducted the biomarker quantification. NP has received personal speaker fees from Servier, Takeda and Novo Nordisk, and advisory board activities from Astra Zeneca and Novo Nordisk. He has also received grants for his research group relating to type 2 diabetes mellitus from Diabetes UK, NIHR EME, Julius Clinical and the British Heart Foundation. He holds no stocks and shares in any such company. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.